Results 211 to 220 of about 52,894 (243)

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres

International Journal of Pharmaceutics, 2004
The purpose of this study was to compare the combination (Paclitaxel + 5-FU microspheres) with a single drug chemotherapy (Paclitaxel and 5-FU microspheres) against metastatic breast cancer cell line (MDA-MB 435 S). The physicochemical characteristics of the microspheres (i.e.
Anshul, Gupte, Kadriye, Ciftci
openaire   +2 more sources

Effects of 5-FU

2010
5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cell proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis.
Peter M, Wigmore, Sarah, Mustafa, Maha, El-Beltagy, Laura, Lyons, Jariya, Umka, Geoff, Bennett   +5 more
openaire   +2 more sources

Conversion of a Nŏvel 5-Fluorouracil (5-FU) Derivative to 5-FU in Rats

Journal of Urology, 1983
The converting efficiency of a novel 5-FU derivative, 1, 3-didecanoyl-2-[6-[(5-fluorouracil-l-yl) carbonylamino] hexanoyl]glyceride (DFUG), to 5-FU was investigated in rat plasma. The degradation half-life of DFUG was 4.04 min when DFUG was incubated in rat plasma at 37 degrees C, though DFUG was considerably stable in buffers having different pH ...
K, Takada, H, Yoshikawa, S, Muranishi
openaire   +2 more sources

Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs

Journal of Pharmaceutical Sciences, 2003
The 3-alkylcarbonyloxymethyl-5-fluorouracil (3-ACOM-5-FU) prodrugs have been characterized by their solubilities in isopropyl myristate (S(IPM)) and partition coefficients between IPM and pH 4.0 buffer (K(IPM:AQ)). Estimated S(AQ) values have been obtained from S(AQ) = S(IPM)/K(IPM:AQ.) The abilities of the prodrugs to deliver total 5-FU species from ...
William J, Roberts, Kenneth B, Sloan
openaire   +2 more sources

Cyclophosphamide plus 5-FU versus 5-FU Alone in Advanced Gastric Carcinoma

Oncology, 1985
30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2-5, beginning on day 8.
R T, Chlebowski, J M, Weiner, I, Silverberg, A, Glass, J R, Bateman   +4 more
openaire   +2 more sources

Acute Encephalopathy Attributed to 5‐FU

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996
Acute encephalopathy attributable to 5‐fluorouracil (5‐FU) is rare. A patient experienced this reaction associated with a continuous 5‐FU infusion. The etiology of the event remains uncertain, but it is generally reversible and does not preclude retreatment with 5‐FU at reduced dosages. Steroids and thiamine may expedite neurologic recovery.
C J, Langer, A, Hageboutros, D D, Kloth, D, Roby, A H, Shaer   +4 more
openaire   +2 more sources

Colorectal cancer—Is there an alternative to 5-FU?

European Journal of Cancer, 1997
info:eu-repo/semantics ...
openaire   +3 more sources